Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
07:00am, Tuesday, 29'th Oct 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
07:30am, Saturday, 19'th Oct 2024
Yes, bargains can still be found in the stock market.
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
07:00am, Tuesday, 15'th Oct 2024
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
10:40am, Friday, 11'th Oct 2024
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.
1 Under-the-Radar Biotech Stock to Buy and Hold
07:32am, Sunday, 29'th Sep 2024
Axsome Therapeutics' revenue is growing rapidly. The company's pipeline should lead to many new approvals and label expansions.
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
12:35pm, Thursday, 05'th Sep 2024
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025.
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
12:35pm, Wednesday, 04'th Sep 2024
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
07:00am, Wednesday, 04'th Sep 2024
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
07:00am, Wednesday, 21'st Aug 2024
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
12:06pm, Thursday, 15'th Aug 2024
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDA
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
03:45pm, Tuesday, 06'th Aug 2024
Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losse
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
12:30pm, Monday, 05'th Aug 2024
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
Why Axsome Therapeutics Stock Is Sinking Today
12:15pm, Monday, 05'th Aug 2024
Axsome's Q2 revenue beat estimates, but the company posted a wider net loss than expected. The primary culprit behind the disappointing bottom line were noncash charges of $26 million.
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
11:20am, Monday, 05'th Aug 2024
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick
